PAVmed (PAVM)
(Delayed Data from NSDQ)
$0.41 USD
-0.05 (-11.68%)
Updated Aug 7, 2025 03:59 PM ET
After-Market: $0.40 -0.01 (-2.44%) 4:32 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PAVM 0.41 -0.05(-11.68%)
Will PAVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PAVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PAVM
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
Lucid Inks New Partnership With VITALExam: Stock to Gain?
PAVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates
Other News for PAVM
PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025 | PAVM Stock News
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule | ...
PAVmed gets 180-day extension to regain Nasdaq listing compliance
Lucid says meeting scheduled to determine Medicare coverage for cancer test
PAVmed Inc. Completes First in Human Trial of PortIO Intraosseous Infusion System